Dr. Felip Discusses Ceritinib's Response in ALK+ NSCLC

Enriqueta Felip, MD, PhD
Published: Wednesday, Nov 12, 2014

Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).

Felip says that two groups of patients in the trial were treated with ceritinib. Of the 246 patients enrolled in the study, 83 patients were crizotinib-naïve and the rest were crizotinib-resistant. The study showed that the response rate was 72% in the patients that were crizotinib-naïve and 56% among the patients that were crizotinib-resistant.

More importantly, Felip says, patients that were crizotinib-naïve had a median progression-free survival of 18.4 months.

​
Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).

Felip says that two groups of patients in the trial were treated with ceritinib. Of the 246 patients enrolled in the study, 83 patients were crizotinib-naïve and the rest were crizotinib-resistant. The study showed that the response rate was 72% in the patients that were crizotinib-naïve and 56% among the patients that were crizotinib-resistant.

More importantly, Felip says, patients that were crizotinib-naïve had a median progression-free survival of 18.4 months.

​

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x